Roivant Sciences Ltd to Provide Update Regarding Initiation of Patent Litigation Against Moderna - Conference Call Transcript
Good day, and thank you for standing by. Welcome to Roivant's update regarding Initiation of Patent Litigation Against Moderna Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Paul Davis. Please go ahead.
Great. Good morning, and thank you for joining today's call to discuss the initiation of patent litigation against Moderna by Genevant and its licensor Arbutus. I'm Paul Davis, the Head of Communications at Roivant. On the call today, we have Roivant's CEO, Matt Gline; and Dr. Pete Lutwyche, CEO of Genevant.
For those dialing in via conference call, you can find the slides being presented today on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. We will end the call with a Q&A session.
I'd like to remind
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |